19 C
New York
Friday, June 9, 2023

Is Cara Therapeutics Inc. (NASDAQ: CARA) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Cara Therapeutics Inc. (CARA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.03, or 0.85%, to $3.54. The Cara Therapeutics Inc. has recorded 6,006 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus.

<25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Stocks Info

CARA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $3.51 and fluctuated between $3.6900 as its day high and $3.5050 as its day low. The current market capitalization of Cara Therapeutics Inc. is $192.45M. A total of 0.61 million shares were traded on the day, compared to an average of 749.64K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, CARA has seen 0 BUY and 7 SELL insider trades, representing the acquisition of 0 and the disposition of 32,961 shares. Over the last 12 months, there were 6 BUYs and 18 SELLs from insiders. Insiders purchased 78,756 shares during that period but sold 89,076.

In the most recent transaction, Posner Christopher sold 3,869 shares of CARA for 4.40 per share on May 05. After the transaction, the President and CEO now owns 172,514 company shares. In a previous transaction on Apr 04, Menzaghi Frederique Ph.D. sold 2,733 shares at 4.91 per share. CARA shares that Chief Scientific Off,SVP-R&D owns now total 156,740.

Among the insiders who sold shares, Terrillion Scott disposed of 2,481 shares on Apr 04 at a per-share price of $4.91. This resulted in the Sec’y; Chief Compliance & G.C. holding 91,046 shares of CARA after the transaction. In another insider transaction, Goncalves Joana sold 2,481 shares at $4.91 per share on Apr 04. Company shares held by the Chief Medical Officer now total 56,404.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for CARA in the last 3 months, the mean price target is $17.63 with high estimates of $28.00 and low estimates of $4.00. In terms of 52-week highs and lows, CARA has a high of $12.98 and a low of $3.67.

As of this writing, CARA has an earnings estimate of -$0.51 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.44 per share and a lower estimate of -$0.6. The company reported an EPS of -$0.56 in the last quarter, which was -75.00% lower than expectations of -$0.32.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. CARA’s latest balance sheet shows that the firm has $167.03M in Cash & Short Term Investments as of fiscal 2021. There were $3.67M in debt and $17.62M in liabilities at the time. Its Book Value Per Share was $2.54, while its Total Shareholder’s Equity was $227.52M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CARA is Buy with a score of 4.50.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles